RTW Investments LP Makes New Investment in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

RTW Investments LP purchased a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 11,764,000 shares of the company's stock, valued at approximately $18,587,000. RTW Investments LP owned 33.65% of RAPT Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the business. Picton Mahoney Asset Management grew its position in shares of RAPT Therapeutics by 994.4% in the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock valued at $26,000 after buying an additional 14,697 shares during the last quarter. Los Angeles Capital Management LLC boosted its holdings in RAPT Therapeutics by 9.2% in the fourth quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company's stock valued at $348,000 after acquiring an additional 18,558 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in RAPT Therapeutics by 298.2% in the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock valued at $34,000 after acquiring an additional 25,130 shares during the last quarter. Barclays PLC increased its position in RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company's stock valued at $79,000 after purchasing an additional 29,195 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of RAPT Therapeutics by 4.9% in the 4th quarter. Geode Capital Management LLC now owns 716,937 shares of the company's stock worth $1,133,000 after purchasing an additional 33,758 shares during the period. Institutional investors and hedge funds own 99.09% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of RAPT Therapeutics in a research report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, RAPT Therapeutics has a consensus rating of "Hold" and an average target price of $4.00.

RAPT Therapeutics Stock Performance

Shares of RAPT stock traded up $0.13 during mid-day trading on Monday, hitting $0.97. The company's stock had a trading volume of 1,026,416 shares, compared to its average volume of 1,264,351. RAPT Therapeutics, Inc. has a 52 week low of $0.71 and a 52 week high of $4.83. The company's fifty day simple moving average is $1.00 and its 200-day simple moving average is $1.21. The company has a market cap of $128.04 million, a PE ratio of -0.35 and a beta of -0.04.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.23. On average, equities analysts anticipate that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.